Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Danuglipron: Evidence Summary
Evidence summary for Danuglipron across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Danuglipron overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Obesity/weight loss | Tier B | 1 | Phase 2b RCT (N=610) showed 8-13% weight loss at 32 weeks |
| Type 2 diabetes | Tier B | 1 | Phase 2 RCT (N=411) demonstrated glycemic control |
| MASH/NAFLD | Tier D | 0 | No trials — theoretical benefit from GLP-1 class |
References (2)
- Phase 2b trial of danuglipron in adults with obesity — Pfizer Clinical Trial Investigators . Obesity (2025)
- Phase 2 trial of danuglipron in Type 2 diabetes — Pfizer Clinical Trial Investigators . Diabetes Care (2023)